Uncategorized
Eleven Biotherapeutics completes patient enrollment for phase 3 study of isunakinra
Eleven Biotherapeutics has completed patient enrollment for the pivotal phase 3 study of isunakinra in patients with allergic conjunctivitis, the company announced in a press release. Isunakinra (EBI-005) is a topical interleukin-1 receptor blocker under study for use in moderate to severe allergic conjunctivitis. A total of 258 patients were randomized 1:1 to receive treatment with isunakinra or vehicle control in the multicenter, double-masked study. Safety and efficacy will be evaluated for up to 4½ weeks.